At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin and Placebo for Acute Heart Failure and Heart Failure. Completed, enrolled 2,401 participants across 1 site.
Signals
Detailed Summary
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
Study Details
Timeline
Arms & Interventions
Dapagliflozin 10 mg administered orally once daily for 2 months
Matching placebo administered orally once daily for 2 months
Interventions
Dapagliflozin
Matched placebo